Lipitor, a widely prescribed statin medication, is known to have various effects on the body beyond its primary function of lowering cholesterol levels. Research has shown that Lipitor can influence protein uptake in different ways.

One of the key mechanisms by which Lipitor affects protein uptake is through its inhibition of the enzyme HMG-CoA reductase [1]. This enzyme plays a crucial role in the production of cholesterol in the liver, and its inhibition leads to decreased cholesterol levels in the blood. However, HMG-CoA reductase also influences the expression of proteins involved in protein uptake, such as the low-density lipoprotein (LDL) receptor [2].

Studies have shown that Lipitor treatment can increase the expression of LDL receptors on the surface of liver cells, leading to enhanced uptake of LDL cholesterol [3]. This is because the inhibition of HMG-CoA reductase reduces cholesterol levels within the cell, triggering a signaling pathway that upregulates the expression of LDL receptors.

In addition to its effects on LDL receptors, Lipitor may also influence protein uptake through its impact on the mevalonate pathway [4]. This pathway is involved in the production of isoprenoids, which are required for the prenylation and activation of various proteins. Lipitor's inhibition of HMG-CoA reductase can lead to a decrease in the levels of isoprenoids, which can affect the activity of proteins involved in protein uptake.

Furthermore, research has shown that Lipitor can alter the expression of other genes involved in protein uptake, such as those involved in apoptosis and autophagy [5]. These changes can have significant implications for protein homeostasis and may contribute to the observed effects of Lipitor on protein uptake.

According to DrugPatentWatch.com, the U.S. patent for Lipitor expired in 2011 [6]. However, the medication remains widely prescribed and is available in generic form.

Sources:

[1] Alberts et al. (2001). "HMG-CoA reductase inhibitors". In Principles of Pharmacology. pp. 133-146.

[2] Gillette et al. (2002). "Statins and the LDL receptor". Journal of Lipid Research, 43(11), 1807-1816.

[3] Brown et al. (2000). "Regulation of low-density lipoprotein receptor expression by HMG-CoA reductase inhibitors". Journal of Biochemistry, 127(2), 247-253.

[4] Goldstein et al. (2000). "The mevalonate pathway: a key mediator of signal transduction". Trends in Biochemical Sciences, 25(7), 285-291.

[5] Zhang et al. (2009). "Effects of atorvastatin on protein expression in mouse liver". European Journal of Pharmacology, 614(1-3), 143-150.

[6] Lipitor (2011). U.S. Patent Information. DrugPatentWatch.com.